AI assistant
Sending…
Rua Bioscience Limited — Capital/Financing Update 2025
Jan 6, 2025
66262_rns_2025-01-06_3c833dc9-1570-45e9-92e7-856489b8000a.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Capital Change Notice
==> picture [78 x 33] intentionally omitted <==
| Section 1: Issuer inform | |||||
| Section 1: Issuer inform | ation | ||||
| Name of issuer | Rua Bioscience Limited | ||||
| NZX ticker code | RUA | ||||
| Class of financial product | |||||
| Ordinary shares | |||||
| ISIN (If unknown check o | n NZX website) | NZRUAE0004S1 | |||
| , | |||||
| C | NZ$ | ||||
| urrency | |||||
| Section 2: Capital chang | e details | ||||
| Number issued/acquired/r | |||||
| deemed | 4000000 | ||||
| ,, | |||||
| Nominal value (if any) | |||||
| N/A | |||||
| Issue/acquisition/redempti | |||||
| on price per security | $0.025 | ||||
| Nt f th t f | l h th | Ch | |||
| aure o e paymen (orconsideration) | exampe, cas or oer | as | |||
| At id if t i f | ll | Pid i fll | |||
| moun pa up ( no n | ) | a n u | |||
| Percentage of total class oid/id/d | f Financial Products | 1.86% | |||
| / lltd th b f | |||||
| ssueacqurereeemeFinancial Products of the C | (cacuae on e numer o | ||||
| lass, excluding any Treasury Sto | ck, | ||||
| in existence)1 | |||||
| For an issue of Convertibl | e Financial Products or Options, th | e | N/A | ||
| principal terms of Conversion (for example the Conversionprice and Conversion date and the ranking of the FinancialProduct in relation to other Classes of Financial Product) or theOption (for example the exercise price and exercise date) | |||||
| , | |||||
| Reason for issue/acquisiti | on/redemption and specific authori | ty | Allotment of new ordinary | ||
| for issue/acquisition/redembe identified here) | ption/ (the reason for change mu | t | shares pursuant to shortfallapplications as per the offer | ||
| announced on 6 November2024 | |||||
| . | |||||
| Total number of Financial | Products of the Class after the | 218,848,012 ordinary shares | . | ||
| issue/acquisition/redempti | n/Conversion (excludin Treasur | ||||
| g | ss | ||||
| Stock) and the total numbhld T Stk ft | er of Financial Products of the Cla | ||||
| th i/iiti/dti | |||||
| e as reasury oc a | er e ssueacqusonreempo | . | |||
| In the case of an acquisitio | n of shares, whether those shares | N/A | |||
| are to be held as treasury | stock | ||||
| Specific authority for the isincluding a reference to thacquisition or redemption | sue, acquisition, or redemption, | Board resolutions and NZX | |||
| e rule pursuant to which the issue, | Listing Rule 4.3.1(a) and 4.4 | ||||
| is made | |||||
| , | |||||
| T dtil f th i | iiti dti f | I f di h hi | hy | ||
| erms or eas o e ssexample: restrictions, escr | e, acquson, or reempon (or | ssue o ornary sares wc | |||
| ow arrangements) | rank equally with all other full | ||||
| paid ordinary shares | |||||
| Date of issue/acquisition/r | edemption | 06/01/2025 | |||
1 The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.
| Section 3: Authority for this announcement and contact person | Section 3: Authority for this announcement and contact person |
|---|---|
| Name of person authorised to make this announcement | Paul Naske |
| Contact person for this announcement | Paul Naske |
| Contact phone number | 021 445 154 |
| Contact email address | [email protected] |
| Date of release through MAP | 06/01/2025 |
More from Rua Bioscience Limited
Director's Dealing
2026
May 22
Share Issue/Capital Change
2026
May 21
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 12
Interim / Quarterly Report
2026
Feb 26
Director's Dealing
2026
Jan 20
Major Shareholding Notification
2026
Jan 20
Director's Dealing
2026
Jan 19
Director's Dealing
2026
Jan 19
Major Shareholding Notification
2026
Jan 15